Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.06.2021 | editorial

Immunotherapy revisited

verfasst von: Assoc. Prof. PD Dr. Thorsten Füreder

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Excerpt

Immunotherapy has revolutionized cancer treatment during the last few years. Impressive long-term survival rates (beyond 5 years) even in deadly diseases such as metastatic lung cancer or malignant melanoma were achieved by checkpoint inhibitor (CPI) therapy. …
Nächster Artikel Treatment approaches towards physical activity – malnutrition – cognitive impairment
Literatur
1.
2.
3.
4.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–46.CrossRef
5.
Jacobson C, Locke FL, Ghobadi A, et al  Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel). Blood 2020; 136 (Supplement 1): 40–42. https://​doi.​org/​10.​1182/​blood-2020-134362.
6.
Aguiar PN Jr., Santoro IL, Tadokoro H, et al. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy. 2016;8:479–88.CrossRef
Metadaten
Titel
Immunotherapy revisited
verfasst von
Assoc. Prof. PD Dr. Thorsten Füreder
Publikationsdatum
01.06.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00711-7

Weitere Artikel der Ausgabe 2/2021

European Society for Medical Oncology 2020

  • editorial

ESMO 2020: highlights in breast cancer

  • Open Access
  • short review

memo—publisher’s report 2020

  • editorial

Are there still indications for whole brain irradiation in 2021?

  • Open Access
  • short review

ESMO 2020 update: Pancreatic cancer

  • Open Access
  • short review

Cognitive impairment in cancer patients and survivors—clinical presentation, pathophysiology, diagnosis and management

  • review